A pancreatic cancer patient argues that critiques of survival data (e.g., a 7-month gain) miss the point. For individuals with a terminal diagnosis, these 'numbers on a screen' represent invaluable time with family, making any extension profoundly meaningful.
A patient on an experimental pancreatic cancer drug emphasized that its greatest benefit was giving her 10 months of a normal life back—working and being a mother and wife. This highlights how quality of life can be as crucial to patients as traditional efficacy endpoints.
A patient described her decision to enter a trial as abandoning the 'safety net' of chemotherapy. Even though chemo is harsh, it's a known quantity. This reveals the significant emotional barrier patients must cross to join a trial, a process clinicians must handle with care.
Unlike other sectors, biotech is an industry where a single data release can result in a 5x gain or a 99% loss. This volatility, driven by complex and nuanced clinical data, makes it fundamentally unsuited for the binary 'good or bad' analysis common in generalist investing.
The presentation of Revolution Medicine's pancreatic cancer data was interrupted by a standing ovation from thousands of oncologists at ASCO. This rare, emotional outburst serves as a powerful, real-time signal of the data's profound impact and acceptance by the medical community.
Abivax's stock plummeted despite best-in-class efficacy for its ulcerative colitis drug. Investors fixated on a few cancer cases deemed unrelated to the treatment, showing extreme risk aversion to new biological pathways where long-term safety is uncertain.